Researchers surveyed 53,310 participants to discover whether PPI use increased the odds of acquiring COVID-19.
What you should know:
1. Of all participants, 3,386 patients reported a positive COVID-19 test.
2. In a regression analysis, individuals using PPIs either once or twice a day had higher COVID-19 infection rates than those not taking PPIs.
3. Patients taking histamine-2 receptor antagonists did not face an elevated risk.
Brennan M. R. Spiegel, MD, of Los Angeles-based Cedars-Sinai commented on the study, saying: “We found a strong, independent effect of using PPIs on risk of COVID-19, including a dose-response relationship with nearly a four-fold increased risk for twice daily dosing. But we found no relationship with the less powerful H2RAs, such as famotidine or cimetidine.”
More articles on surgery centers:
Top-paying jobs in 2020 — Surgeons are No. 1
The state of ASCs in June 2020: 10 observations on supply chain, payers, staffing & future growth
Optum leads $26M funding round for digital therapeutics startup
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.